-
Chapter and Conference Paper
Treatment of Metastatic Melanoma with Interferon-α and Interleukin-2: Significant Improvement with a New Dosing Schedule
Interleukin-2 (IL-2) has been used since 1984 as a single agent or in combination with lymphokine-activated killer cells [l–4] to treat human malignancies. More recently a combination therapy of interferon-alp...
-
Chapter and Conference Paper
Induction Therapy for Acute Myelogenous Leukemia with Idarubicin/Cytosine Arabinoside and Mitoxantrone/Etoposide in “Response-Adapted” Sequence
With conventional induction chemotherapy 47%–72% of adult patients with acute myelogenous leukemia (AML) achieve complete remission (CR). However, the probability of continuous CR ranges from 8% to 45% at 3 ye...
-
Chapter and Conference Paper
The Interleukin-2 Receptor (CD25 and p75) in Human Monocytes and Macrophages
Interleukin-2 (IL-2) is secreted by T-cells upon antigen presentation and induces proliferation and activation of lymphocytes. It was also shown to induce monocyte (MO) functions, including tumor cytotoxicity ...
-
Chapter and Conference Paper
Regional Adoptive Immunotherapy for Hepatic Metastasis
Adoptive immunotherapy has proved to be effective in certain human cancers. To improve the efficacy of this treatment modality, we developed a protocol for regional treatment of hepatic metastasis. A regional ...
-
Chapter
The Plasmacytoid T Cell or Plasmacytoid Monocyte — A Sessile Lymphoid Cell with Unique Immunophenotype and Unknown Function, Still Awaiting Lineage Affiliation
Plasmacytoid T cells (PTCs) were first described in 1958, as clusters of cells with the light-microscopic appearance of “lymphoblasts” (Lennert and Remmele 1958). The electron-microscopic features conformed to th...